Shilpa Pharma

Full-spectrum peptide CDMO offering SPPS, LPPS, hybrid, recombinant, and native chemical ligation synthesis. cGMP peptide manufacturing from preclinical to commercial scale. Advanced modifications including lipidation, PEGylation, cyclization, and disulfide bridging.

Directory assessment: Shilpa Pharma is listed as a CDMO in the peptide supply chain, serving Asia markets from India. As a direct manufacturer, this supplier controls its own production process from synthesis through purification and quality control release testing. Verification is based on publicly available information and cross-referenced against industry databases. This supplier has a medium confidence score — verification signals are present, but the listing is newer or less documented; perform standard due diligence before engaging.